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Abstract 30 
To generate energy efficiently, the cell is uniquely challenged to co-ordinate the abundance of 31 
electron transport chain protein subunits expressed from both nuclear and mitochondrial genomes. 32 
How an effective stoichiometry of this many constituent subunits is co-ordinated post-33 
transcriptionally remains poorly understood.  Here we show that Cerox1, an unusually abundant 34 
cytoplasmic long noncoding RNA (lncRNA), modulates the levels of mitochondrial complex I subunit 35 
transcripts in a manner that requires binding to microRNA-488-3p.  Increased abundance of Cerox1 36 
cooperatively elevates complex I subunit protein abundance and enzymatic activity, decreases 37 
reactive oxygen species production, and protects against the complex I inhibitor rotenone.  Cerox1 38 
function is conserved across placental mammals: human and mouse orthologues effectively 39 
modulate complex I enzymatic activity in mouse and human cells, respectively. Cerox1 is the first 40 
lncRNA demonstrated, to our knowledge, to regulate mitochondrial oxidative phosphorylation and, 41 
with miR-488-3p, represent novel targets for the modulation of complex I activity. 42 
  43 
 3 
 
Introduction 44 
In eukaryotes, coupling of the mitochondrial electron transport chain to oxidative phosphorylation 45 
(OXPHOS) generates the majority of ATP that fulfils cellular energy requirements.  The first enzyme 46 
of the electron transport chain, NADH:ubiquinone oxidoreductase (complex I), catalyses the transfer 47 
of electrons from NADH to coenzyme Q10, pumps protons across the inner mitochondrial 48 
membrane and produces reactive oxygen species (ROS).   Mammalian mitochondrial complex I 49 
dynamically incorporates 45 distinct subunits into a ~1 MDa mature structure (1, 2). It is known that 50 
oxidatively damaged subunits can be exchanged in the intact holo-enzyme (3), but how this process 51 
may be regulated is poorly understood.  The efficiency and functional integrity of OXPHOS are 52 
thought to be partly maintained through a combination of tightly co-ordinated transcriptional and 53 
post-transcriptional regulation (4-6) and specific sub-cytoplasmic co-localisation (7, 8). The nuclear 54 
encoded subunits are imported into the mitochondria after translation in the cytoplasm and their 55 
complexes assembled together with the mitochondrially encoded subunits in an intricate assembly 56 
process (9-11). Mitochondrial biogenesis is co-ordinated first transcriptionally from both genomes 57 
(12), and then post-transcriptionally by regulatory small noncoding RNAs such as microRNAs 58 
(miRNAs) (13, 14).  Recently, SAMMSON a long noncoding RNA (lncRNA) was found to bind p32 and, 59 
within mitochondria, enhanced the expression of mitochondrial genome-encoded polypeptides (15). 60 
 61 
Nuclear-encoded and cytosol-located lncRNAs have not yet been implicated in regulating 62 
mitochondrial OXPHOS (16) despite being surprisingly numerous and often found localised to 63 
mitochondrion- and ribosome-adjacent portions of the rough endoplasmic reticulum (17). It is here, 64 
on the ribosome, that turnover of miRNA-targeted mRNAs frequently occurs during their translation 65 
(18). Here we describe a novel mammalian conserved lncRNA, termed Cerox1 (cytoplasmic 66 
endogenous regulator of oxidative phosphorylation 1). Cerox1 regulates complex I activity by co-67 
ordinately regulating the abundance of at least 12 complex I transcripts via a miRNA-mediated 68 
mechanism. Cerox1 knockdown decreases the enzymatic activities of complexes I and IV.  69 
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Conversely, elevation of Cerox1 levels increases their enzymatic activities, halves cellular oxidative 70 
stress, and protects cells against the cytotoxic effects of the complex I inhibitor rotenone. To our 71 
knowledge, Cerox1 is the first lncRNA modulator of normal mitochondrial energy metabolism 72 
homeostasis and cellular redox state. The miRNA-dependency of Cerox1 and the regulation of 73 
associated OXPHOS transcripts are supported by: (i) direct physical interaction of miR-488-3p with 74 
Cerox1 and complex I transcripts; (ii) decrease or increase in Cerox1 and complex I transcripts 75 
following miR-488-3p overexpression or inhibition, respectively; (iii) miR-488-3p destabilisation of 76 
wildtype Cerox1, but not a Cerox1 transcript containing a mutated miR-488-3p miRNA recognition 77 
element (MRE) seed region; and, (iv) absence of the OXPHOS phenotypes either in cell lines deficient 78 
in microRNA biogenesis or when Cerox1’s predicted miR-488-3p response element is mutated.  The 79 
miRNA-dependent role of Cerox1 illustrates how RNA-interaction networks can regulate OXPHOS 80 
and that lncRNAs represent novel targets for modulating OXPHOS enzymatic activity.   81 
 82 
 83 
RESULTS 84 
Cerox1 is a conserved, highly expressed long noncoding RNA  85 
Cerox1 was selected for further investigation from among a set of central nervous system-derived 86 
polyadenylated long non-coding RNAs identified by cDNA sequencing (GenBank Accession 87 
AK079380, 2810468N07Rik) (19, 20). Mouse Cerox1 is a 1.2 kb, two exon, intergenic transcript which 88 
shares a bidirectional promoter with the SRY (sex determining region Y)-box 8 (Sox8) gene (Figure 89 
1A). A human orthologous transcript (CEROX1, GenBank Accession BC098409) was identified by 90 
sequence similarity and conserved synteny (60-70% nucleotide identity within alignable regions, 91 
Figure 1B,C).  Both mouse and human transcripts have low protein coding potential (Methods, Figure 92 
1 – figure supplement 1A) and no evidence for translation from available proteomic datasets.    93 
 94 
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Four human or mouse data types supported CEROX1 as having an important organismal role.  First, 95 
its promoter shows a greater extent of sequence conservation than the adjacent SOX8 promoter and 96 
its exons are conserved among eutherian mammals (Figure 1B). Second, from expression data, its 97 
levels in primary tissues and cells are exceptionally high, within the top 13% of a set of 879 lncRNAs 98 
with associated cap analysis of gene expression (CAGE) clusters (Figure 1D,E). Expression is 99 
particularly high in neuroglia, neural progenitor cells and oligodendrocyte progenitors (21-23) 100 
(Figure 1 – figure supplement 1B). Cerox1 is notable in its higher expression in the adult brain than 101 
64% of all protein coding genes. Cerox1 expression is also developmentally regulated. For example, it 102 
is a known marker gene for type 1 pre-haematopoietic stem cells in the dorsal aorta (24) and its 103 
expression is high in mouse embryos beyond the 21 somite stage (https://dmdd.org.uk/). High 104 
expression of Cerox1 in the brain was confirmed using quantitative real-time PCR (qPCR) for both 105 
mouse and human orthologous transcripts (Figure 1 – figure supplement 1C,D). 106 
 107 
Third, single nucleotide variants are significantly associated both with CEROX1 expression and 108 
anthropomorphic traits, measured in the UK Biobank. These lie within an 85kb interval 109 
encompassing the CEROX1 locus, and 5’ regions of SOX8 and LMF1 genes. For example, rs3809674 is 110 
significantly associated with standing and sitting heights; arm fat-free mass (left or right); arm 111 
predicted mass (left or right); trunk fat-free or predicted mass; and whole body fat-free mass 112 
(p<5x10-8, Supplementary file 1); this variant is also a CEROX1 expression quantitative trait locus 113 
(eQTL) for 30 GTEx tissues (p≤0.05), some with absolute normalised effect sizes reaching 0.83 (Figure 114 
1 – figure supplement 1E). Genetically determined expression change in CEROX1 therefore could 115 
explain, in part, variation in these anthropomorphic traits. These variations affect a large fraction of 116 
the human population (minor allele frequency of 28% in 1000 Genomes data). An alternative 117 
interpretation that rs3809674 (and linked variants) act on anthropomorphic traits through LMF1, 118 
rather than CEROX1, is consistent with this variant being an eQTL for LMF1, but is not consistent 119 
with the known protein function of LMF1, a lipase maturation factor, because the associated 120 
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anthropomorphic traits relate only to fat-free mass. A summary-data-based Mendelian 121 
randomization analysis that uses rs3809674 as an instrumental variable, predicts an effect of 122 
CEROX1 gene expression on glioma risk (25).  Finally, it has recently been demonstrated in a mouse 123 
model of haematopoietic lineage differentiation that Cerox1 depletion impairs the contributions of 124 
stem and progenitor cells to haematopoiesis (26). 125 
  126 
In mouse neuroblastoma (N2A) cells the most highly expressed Cerox1 transcript (Figure 1 – figure 127 
supplement 1F,G) is enriched in the cytoplasmic fraction (Figure 1F) with a short half-life of 36 ± 16 128 
mins (Figure 1 – figure supplement 1H) and is mainly associated with the ribosome-free fraction 129 
(Figure 1 – figure supplement 1I).  130 
 131 
Figure 1. Cerox1 is an evolutionarily conserved, highly expressed and predominantly cytoplasmic 132 
lncRNA. (A) The mouse Cerox1 locus (mm9 assembly). Sequence shaded in blue highlights 133 
conservation within exon two among eutherian mammals, but not in non-mammalian vertebrates 134 
such as chicken and zebrafish. (B) Syntenic human locus (hg19). This transcript was previously 135 
identified on the minus strand as LMF1 non-coding transcript 4, and is located within the intron of 136 
LMF1 non-coding transcript 2. LMF1 non-coding transcript 2 is annotated as a nonsense mediated 137 
decay biotype.  A prominent peak of H3K4me3 (tri-methylation of histone H3 lysine 4 often found 138 
near promoters) modification marks the CEROX1 transcriptional start site.  H3K4me3 peaks for H7-139 
human embryonic stem cells (H7-hESC), human skeletal muscle myoblasts (HSMM) and human 140 
embryonic kidney 293 cells (HEK293) are depicted.  The genomic evolutionary rate profiling (GERP) 141 
score indicates a higher extent of conservation of the CEROX1 promoter (shaded pink) than the 142 
adjacent SOX8 promoter (shaded green). (C) Schematic representation of mouse Cerox1 transcript 143 
and the human orthologous sequence. Exon two contains blocks of 60-70% sequence identity; 144 
human CEROX1 has an additional 1235 bases of retrotransposed insertions at the 5’ end. (D) 145 
Distributions of lncRNAs’ and protein-coding genes’ average expression levels across tissues in 146 
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mouse.  Average expression levels of representative mitochondrial complex I subunits’ mRNAs are 147 
indicated. TPM = tags per million. (E) Average expression levels of Cerox1 across mouse tissue 148 
samples. The orange bar highlights nervous system tissue samples whose values for replicates 149 
among neurological tissues are shown in the inset panel: 1- Medulla oblongata, 2– Spinal cord, 3– 150 
Diencephalon, 4– Substantia nigra, 5– Microglia, 6– Raphe, 7– Dorsal spinal cord, 8– Corpora 151 
quadrigemina, 9– Cortex, 10– Corpus striatum, 11- Visual cortex, 12– Olfactory brain, 13– 152 
Cerebellum, 14– Neurospheres sympathetic neuron derived, 15– Neurospheres parasympathetic 153 
neuron derived, 16– Neurospheres enteric neuron derived, 17– Astrocytes (cerebellar), 18– 154 
Hippocampus, 19– Hippocampal, 20– Ventral spinal cord, 21– Astrocytes, 22– Pituitary gland, 23– 155 
Astrocytes (hippocampus), 24– Cortical neurons, 25– Striatal neurons, 26– Schwann cells, 27– 156 
Meningeal cells. Error bars indicate s.e.m. (F) Cytoplasmic localisation of mouse Cerox1 compared to 157 
a nuclear retained lncRNA, Malat1, as demonstrated by fluorescent in situ hybridization and cell 158 
fractionation followed by quantitative PCR. By fractionation, mouse Cerox1 is 15-fold enriched in the 159 
cytoplasm of N2A cells (n = 5; error bars s.e.m.). Scale bar = 5 m. 160 
 161 
Cerox1 expression modulates levels of oxidative phosphorylation transcripts  162 
Expression of Cerox1 was manipulated by transient overexpression or shRNA-mediated knockdown.  163 
Twelve shRNAs were tested for the ability to knock-down Cerox1 (Figure 2 – figure supplement 1A). 164 
One of these (sh92) decreased expression levels by greater than 60%, with the next best shRNA 165 
(sh1159) decreasing expression by approximately 40%.  As expected from their sharing of the 166 
Cerox1-Sox8 bidirectional promoter, CRISPR-mediated activation and inhibition of the Cerox1 locus 167 
was not specific as it led also to changes in Sox8 expression (Figure 1A, Figure 2 – figure supplement 168 
1B).  However, decreasing Cerox1 levels in N2A cells by shRNA or transient overexpression had no 169 
effect on the expression of neighbouring genes (Figure 2 – figure supplement 1C). In contrast, Cerox1 170 
overexpression led to differential expression of 286 distal genes (q < 0.05, Bonferroni multiple 171 
testing correction; Supplementary file 2), of which an unexpected and large majority (83%; 237) 172 
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were upregulated (P < 10-6; binomial test). Our attention was immediately drawn to the considerable 173 
(≥20-fold) enrichment of the mitochondrial respiratory chain gene ontology term among 174 
upregulated genes (Figure 2A).  175 
 176 
The mitochondrial electron transport chain (ETC) consists of five multi-subunit complexes encoded 177 
by approximately 100 genes of which only 13 are located in the mitochondrial genome. The 15 ETC 178 
transcripts that show statistically significant differential expression after Cerox1 overexpression are 179 
nuclear encoded (Figure 2B,C) with the greatest changes observed by qPCR for complex I subunit 180 
transcripts (Figure 2 – figure supplement 1D). Twelve of 35 nuclear encoded complex I subunits or 181 
assembly factors transcripts increased substantially and significantly (>40%) following Cerox1 182 
overexpression; we consider these to be gene expression biomarkers for Cerox1 activity in the 183 
mouse N2A system (Figure 2C).  In the reciprocal Cerox1 knock-down experiment, all 12 were 184 
reduced in abundance using sh92, 3 significantly, with a concordant pattern observed for the less 185 
effective shRNA, sh1159 (Figure 2 – figure supplement 1E, F). Taken together, these results indicate 186 
that Cerox1 positively and co-ordinately regulates the levels of many mitochondrial complex I 187 
transcripts.   188 
 189 
Increased abundance of OXPHOS subunit transcripts, following Cerox1 overexpression, was found to 190 
elevate protein levels. Western blots using reliable antibodies for the key complex I catalytic core 191 
proteins NDUFS1 and NDUFS3 showed approximately 2.0-fold protein level increases that surpassed 192 
their ~1.4-fold transcript level changes (median 2.4 and 1.4-fold increases [P = 0.0013 and 0.002], 193 
respectively; Figure 2D). Cerox1 transcript abundance is thus coupled positively to OXPHOS 194 
transcript levels and to their availability for translation, resulting in an amplification of the amount of 195 
protein produced. In summary, protein subunits of the same complex (Complex I) that are sustained 196 
at high abundance and with long half-lives (27-29) (Figure 2 – figure supplement 1G), and whose 197 
transcripts are stable (29-32) (Figure 2 – figure supplement 1H) and also have very high copy 198 
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numbers in the cell (29, 33), can be increased two-fold, and co-ordinately, by the simple expediency 199 
of increasing the level of this single abundant lncRNA. 200 
 201 
 202 
Figure 2. Cerox1 overexpression elevates levels of OXPHOS transcripts and their encoded proteins. 203 
(A) Gene ontology analysis indicates a significant enrichment of upregulated genes involved in 204 
mitochondrial electron transport, energy production and redox reactions. (B) Four membrane bound 205 
multi-subunit complexes (CI, CII, CIII, CIV) are embedded in the inner mitochondrial membrane and 206 
facilitate transfer of electrons; three of these subunits are also proton pumps which create the 207 
chemiosmotic gradient required for ATP synthase activity, with complex V being ATP synthase. The 208 
subunits vary in size and complexity with Complex I (NADH:ubiquinone oxidoreductase) consisting of 209 
45 subunits, Complex II (succinate dehydrogenase) 4 subunits, Complex III (Ubiquinol:cytochrome c 210 
oxidoreductase) 11 subunits and Complex IV (Cytochrome c oxidase) 13 subunits. Of 15 oxidative 211 
phosphorylation genes whose transcripts were up-regulated following Cerox1 overexpression 53% 212 
were subunits of Complex I, 13% were subunits of Complex III and 33% were subunits of Complex IV. 213 
* indicates core subunits that are essential for activity. Note: subunit NDUFA4 has recently been 214 
reassigned to mitochondrial complex IV (34). (C) qPCR profiling of 35 complex I subunits and 215 
assembly factors (30 nuclear encoded complex I subunits and 5 assembly factors). Transcripts 216 
showing a 1.4 fold, or greater, change in expression after overexpression of Cerox1 are present 217 
within the boxed shaded area.  Fold change of wild-type Cerox1 compared to the control are 218 
indicated in the inset panel.   The transcripts profiled can be characterised into six categories: Core–219 
Q module, subunits responsible for the electron transfer to ubiquinone; Core–N module, subunits 220 
responsible for the oxidation of NADH; Supernumerary subunits– those that are additional to the 221 
core subunits required for the catalytic role of complex I, but do not play a catalytic role themselves. 222 
Many of these subunits may be performing a structural role, but the majority are of unknown 223 
function. The supernumerary subunits can be further subdivided into supernumerary – N module, 224 
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those accessory subunits associated with the NADH oxidation module of CI; supernumerary ACP 225 
(acyl carrier protein) – in addition to being a non-catalytic subunit of CI, NDUFAB1 is also a carrier of 226 
the growing fatty acid chain in mitochondrial fatty acid biosynthesis; assembly factor, proteins that 227 
are required for the correct assembly and integration of CI.  Error bars s.e.m. (n = 3 biological 228 
replicates).  (D) Overexpression of Cerox1 results in large increases in the total protein levels of two 229 
core subunits for which high quality antibodies exist, normalised to the loading control -tubulin 230 
(TUBA1A). NDUFS1 is one of three (NDUFS1, NDUFV1, NDUFV2) core components of the N-module 231 
of Complex I. NDUFS3 is one of four (NDUFS2, NDUFS3, NDUFS7, NDUFS8) core components of the 232 
Complex I Q-module. n = 7 biological replicates for control and overexpression.  2-sided t-test; ** P < 233 
0.01. (E) Overexpression of Cerox1 results in a change in the metabolite profile of N2A cells, with 10 234 
of 66 metabolites measured demonstrating a significant change in the experimental sample after 235 
multiple testing correction (q < 0.05; n = 6 biological replicates for pCAG-control and pCAG Cerox1 236 
overexpression).  N2A cells overexpressing Cerox1 show an increased GSH:GSSG ratio (figure inset, 2-237 
sided t-test; ** P < 0.01).  238 
 239 
These large effects on protein and mRNA copy number are associated with both metabolic and 240 
cellular phenotypes. Ten metabolites are significantly different in N2A cells overexpressing Cerox1 241 
(Figure 2E). These cells show a significant increase in the reduced glutathione to oxidised glutathione 242 
ratio (GSH:GSSG, P = 1.3 x 10-3, Figure 2D Inset) indicative of a more favourable cellular redox state.  243 
Cerox1-overexpressing cells also exhibited a 43% reduction in cell cycle activity, yet without a change 244 
in the proportion of live/dead cells or a deviation from normal cell cycle proportions (Figure 2 – 245 
figure supplement 1I, J, K). Cerox1 levels thus affect the overall timing of cell division.  246 
 247 
Cerox1 can regulate mitochondrial OXPHOS enzymatic activity 248 
Increased translation of some complex I transcripts leads to increased respiration (35) and, more 249 
specifically, to an increase in the enzymatic activity of complex I (36). To address this hypothesis we 250 
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used oxidative phosphorylation enzyme assays to investigate whether changes in expression to a 251 
subset of subunits lead to a change in enzyme activity and oxygen consumption. Indeed, complex I 252 
and complex IV enzymatic activities increased substantially after Cerox1 overexpression (by 22%, P = 253 
0.01; by 50%, P = 0.003, respectively; 2-tailed Student’s t-test; Figure 3A). Such rate increases for 254 
two of the eukaryotic cell’s most abundant and active enzymes were unexpected.  255 
 256 
We next measured oxygen consumption under these conditions using a Seahorse XFe24 Analyzer. 257 
These complexes’ more rapid catalytic rates resulted, unexpectedly, in large increases in: (i) overall 258 
basal oxygen consumption (by 85%), (ii) ATP-linked oxygen consumption (by 107%) and, (iii) 259 
maximum uncoupled respiration (by 59%; P = 5x10-4, P = 1x10-4, P = 4x10-3, respectively, 2-tailed 260 
Student’s t-test; Fig 3B).  These increases in enzyme activities and mitochondrial respiration are 261 
expected to produce persistent and substantial increases beyond the already very high basal rate of 262 
ATP formation (37), due to the long-half lives of the Cerox1 sensitive complex I protein subunits (27-263 
29). 264 
 265 
Conversely, after sh92-mediated Cerox1 knockdown complex I and complex IV enzymatic activities 266 
decreased significantly (by 11%, P = 0.03 and 19%, P = 0.02, respectively; Figure 3C), with 267 
concomitant large decreases in basal oxygen consumption (53%), ATP linked oxygen consumption 268 
(52%) and maximal uncoupled respiration (61%; P = 0.011, P = 0.034, P = 0.042 respectively, 2-tailed 269 
Student’s t-test; Fig 3D).   270 
 271 
These observed changes in enzymatic activity were not due to changes in mitochondria number 272 
because the enzymatic activities of complexes II, III and citrate synthase (Figure 3A,B), and the 273 
mitochondrial-to-nuclear genome ratio (Figure 3 – figure supplement 3A, B), each remained 274 
unaltered by changes in Cerox1 levels.  These data indicate that Cerox1 can specifically and 275 
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substantially regulate oxygen consumption and catalytic activities of complex I and complex IV in 276 
mouse N2A cells. 277 
 278 
 279 
 280 
Figure 3. OXPHOS enzyme activity and oxygen consumption change concordantly and substantially 281 
with Cerox1 level alteration. (A) Enzyme activities in mouse N2A cells 72 hours post-transfection of 282 
Cerox1 overexpression construct. Mouse Cerox1 overexpression in N2A cells results in significant 283 
increases in the catalytic activities of complexes I (22% increase) and IV (50% increase). Complexes II, 284 
III and citrate synthase show no significant change in activity. n = 8 biological replicates for control 285 
and overexpression. (B) Oxygen consumption, by N2A cells overexpressing Cerox1.  Top: normalised 286 
real time oxygen consumption rate in basal conditions and after sequential injections of oligomycin, 287 
FCCP and rotenone/antimycin A.  Bottom: changes in basal, ATP-linked and maximum uncoupled 288 
respiration respectively.  Error bars s.e.m. (n = 5 biological replicates).  (C) sh92-mediated 289 
knockdown of Cerox1 results in significant decreases of Complexes I and IV enzymatic activities 72 290 
hours post transfection; no significant changes were observed for complexes II, III or the citrate 291 
synthase control. n = 8 biological replicates for control and knockdown. The less effective shRNA 292 
(sh1159) also decreased oxygen consumption yet not significantly relative to the control (data not 293 
shown). (D) Oxygen consumption, by Cerox1 knockdown N2A cells.  Top: normalised real time 294 
oxygen consumption rate in basal conditions and after sequential injections of oligomycin, FCCP and 295 
rotenone/antimycin A.  Bottom: changes in basal, ATP-linked and maximum uncoupled respiration 296 
respectively. Error bars s.e.m. (n = 5 biological replicates).   2-tailed Student’s t-test:  ***P < 0.001, 297 
** P < 0.01, * P < 0.05, ns not significant. 298 
 299 
Cerox1 expression can protect cells from oxidative stress  300 
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Complex I deficient patient cells experience elevated ROS production (38). In Cerox1 knockdown N2A 301 
cells ROS levels were increased significantly, by almost 20% (P = 4.2 x 10-6; Figure 4A). Conversely, in 302 
cells overexpressing Cerox1, ROS production was nearly halved (P = 3.5 x 10
-7; Figure 4A), and protein 303 
carbonylation, a measure of ROS-induced damage, was reduced by 35% (P = 1x10-3; Figure 4B). 304 
Knock-down of Cerox1 resulted in a 6.6% increase in protein carbonylation compared to the control 305 
(P = 0.05, data not shown).  The observed Cerox1-dependent reduction in ROS levels is of particular 306 
interest because mitochondrial complex I is a major producer of ROS which triggers cellular oxidative 307 
stress and damage, and an increase in ROS production is a common feature of mitochondrial 308 
dysfunction in disease (39).  309 
 310 
We next demonstrated that the increased activities of complex I and complex IV induced by Cerox1 311 
protect cells against the deleterious effects of specific mitochondrial complex inhibitors, specifically 312 
rotenone and sodium azide (complex I and complex IV inhibitors, 37% and 58% respectively, P < 313 
0.01); conversely, Cerox1-knockdown cells were significantly more sensitive to rotenone and 314 
exposure to heat (12%, P < 0.001 and 11%, P < 0.01 respectively Figure 4C).   Cells overexpressing 315 
Cerox1 and treated with rotenone, a complex I inhibitor, exhibited no significant difference in 316 
protein carbonylation (data not shown). Taken together, these results indicate that elevation of 317 
Cerox1 expression leads to decreased ROS production, decreased levels of oxidative damage to 318 
proteins and can confer protective effects against complex I and complex IV inhibitors. 319 
 320 
 321 
 322 
Figure 4. Cellular oxidative stress and viability depend on Cerox1 levels.  (A) Cerox1 knockdown 323 
increases the production of reactive oxygen species by 20%, whilst Cerox1 overexpression decreases 324 
it by 45% (error bars s.e.m., n = 12 biological replicates).  (B) Protein oxidative damage also 325 
decreases in the overexpression condition compared to the control, as measured by densitometry 326 
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on western blots against carbonylation of amino acid side chains.  n = 6 biological replicates. (C) 327 
Viability of Cerox1 overexpressing and knock-down cells when stressed. N2A cells were stressed by 328 
addition of electron transport chain (ETC) inhibitors (rotenone, CI inhibitor; malonate, competitive 329 
inhibitor of CII; antimycin A, CIII inhibitor; sodium azide, CIV inhibitor; oligomycin, ATP synthase 330 
inhibitor), exposure to environmental stress (heat, ultraviolet radiation), or manipulation of 331 
extracellular osmolarity (NaCl) or extracellular calcium (CaCl2) concentration, for 1 hour and then the 332 
viability of the cells measured using the fluorescent indicator Alamar Blue. Error bars s.e.m. (n = 6 333 
biological replicates for overexpression control, overexpression, knock-down control and knock-334 
down). 2-tailed Student’s t-test:  *** P < 0.001,  ** P < 0.01. 335 
 336 
Increased OXPHOS enzymatic activity is dependent upon miRNA binding to Cerox1 337 
Due to their positive correlation in expression and cytoplasmic localisation we next considered 338 
whether Cerox1 regulates complex I transcripts post-transcriptionally by competing with them for 339 
the binding of particular miRNAs. To address this hypothesis, we took advantage of mouse Dicer-340 
deficient (Dicer
/
) embryonic stem cells that are deficient in miRNA biogenesis (40). We first tested 341 
Cerox1 overexpression in wildtype mouse ES cells and showed that this, again, led to an increase in 342 
transcript levels, specifically of six complex I subunits (Figure 5A), of which four had previously 343 
shown significant changes in N2A cells after Cerox1 overexpression (Figure 2C). In contrast, 344 
overexpression in Dicer
/ cells failed to increase levels of these transcripts (Figure 5A). These 345 
results indicate that Cerox1’s ability to alter mitochondrial metabolism is miRNA-dependent. 346 
 347 
Four miRNA families (miR-138-5p, miR-28/28-5p/708-5p, miR-370-3p, and miR-488-3p) were 348 
selected for further investigation based on the conservation of their predicted binding sites (MREs) 349 
in both mouse Cerox1 and human CEROX1 (Figure 5B). All five MREs conserved in mouse Cerox1 and 350 
human CEROX1 for N2A-expressed miRNAs (Figure 5B Figure 5 – figure supplement 1A) were 351 
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mutated by inversion of their seed regions. This mutated Cerox1 transcript failed to alter either 352 
complex I transcript levels or enzyme activities when overexpressed in mouse N2A cells (Figure 5C, 353 
D). This indicates that Cerox1’s molecular effects are mediated by one or more of these MREs.  354 
 355 
If so, then the overexpression of these miRNAs in turn would be expected to deplete Cerox1 RNA 356 
levels. Indeed, overexpression of each miRNA reduced Cerox1 levels (Figure 5E). Overexpression of 357 
the tissue-restricted miRNA miR-488-3p (Figure 5 – figure supplement 1B, C (41, 42)) caused the 358 
greatest depletion of the Cerox1 transcript (Figure 5E) indicating that this MRE is likely to be 359 
physiologically relevant.  Dual fluorescent RNA in situ hybridization of miR-488-3p and Cerox1 360 
indicates the proximity of these non-coding RNAs within the N2A cell (Figure 5F) and that both 361 
Cerox1 and miR-488-3p are localised in the cytoplasm (Figures 1F, 5F). CEROX1 transcripts are 362 
predominantly (94%) localised to ribosomes (17), as is the destabilisation by microRNAs of mRNAs as 363 
they are being translated (18). Together, these observations imply that Cerox1 and mitochondrial 364 
protein mRNAs are targets of miR-488-3p on ribosomes within the rough ER that forms a network 365 
around mitochondria (43, 44). 366 
 367 
 368 
Figure 5. The effect of Cerox1 on complex I transcript levels is miRNA-dependent.  (A) 369 
Overexpression of Cerox1 in mouse wildtype and Dicer
/ embryonic stem (ES) cells (inset graph). 370 
The overexpression of Cerox1 in wildtype mouse embryonic stem cells results in an increase in 371 
complex I subunit transcripts, with no observed change in expression of two control subunits 372 
(Ndufs2, Ndufv1) that were also unaffected in N2A cells. Overexpression of Cerox1 in Dicer
/
 373 
embryonic stem cells results in no increase in the expression of any complex I subunit.  2-sided t-374 
test; ** P < 0.01, * P < 0.05, ns = not significant. Error bars s.e.m.  n = 3 biological replicates.  (B) 375 
Predicted MREs whose presence is conserved in both the mouse and human Cerox1. Coloured MREs 376 
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indicate those MREs whose presence is conserved between mouse and human and whose miRNAs 377 
are expressed in N2A cells. miRNA site types are as follows:  miR-28-5p, 8mer-A1; miR-138-5p, 6mer; 378 
miR-370-3p, 7mer-m8; miR-488-3p-3p, 7mer-m8; miR-708-5p, 7mer-A1.  The grey predicted MREs 379 
represent those that are conserved, but whose miRNAs are not expressed in N2A cells (miR-125a-3p, 380 
miR-199/199-5p, miR-302ac/520f, miR-485/485-5p, miR-486/486-5p, miR-501/501-5p, miR-654-3p, 381 
miR-675/675-5p). (C) Overexpression of the 5xMRE mutant failed to alter expression of complex I 382 
subunit transcripts that otherwise all increase in abundance following wild-type Cerox1 383 
overexpression.  Fold changes of wildtype Cerox1 or the 5xMRE Cerox1 mutant compared to the 384 
control are indicated in the inset panel.  The numbers of MREs predicted by TargetScan v7.0 (45) in 385 
these transcripts’ 3’UTRs for the four conserved, N2A expressed miRNA families are indicated (see 386 
also Supplementary file 3). Due to known widespread noncanonical miRNA binding (46), predictions 387 
were also extended across the gene body (bracketed MREs).  2-sided t-test; ** P < 0.01, * P < 0.05, 388 
ns = not significant.  Error bars s.e.m.  n = 3 biological replicates.  (D) Overexpression of the 5xMRE 389 
mutant failed to alter OXPHOS enzymatic activity compared to the control for any of the complexes 390 
measured. A one-way ANOVA was applied to test for differences in activities of the mitochondrial 391 
complexes between a control and overexpression of wildtype Cerox1 and the 5xMRE mutant. A post-392 
hoc Dunnett’s test indicated that the overexpression of wildtype Cerox1 resulted, as expected, in 393 
significantly increased complex I and IV activities of 30% and 17% respectively (F [2, 21] = 4.9, P = 394 
0.017; F[2, 20] = 4.6, P = 0.033), while comparisons for the 5xMRE mutant with the control were not 395 
significant. There was no significant difference in the activities of complex II (F[2,19]= 3.5, P = 0.26), 396 
complex III (F[2,19]= 0.08, P = 0.5) or citrate synthase (F[2,20]=2.6, P = 0.42). n = 6 biological 397 
replicates. Significance levels, one-way ANOVA, Dunnett’s post hoc test * P < 0.05.  (E) Four to six 398 
fold overexpression of each of four miRNAs with predicted MREs whose presence is conserved in 399 
both mouse and human Cerox1 resulted in a decrease in Cerox1 transcript level, with overexpression 400 
of miR-488-3p resulting in >90% knock down of Cerox1. This was not observed when the miRNA miR-401 
137-3p, which has no predicted MREs in Cerox1, was similarly overexpressed. Error bars s.e.m.  n = 3 402 
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biological replicates.  (F) Fluorescent in situ hybridisation detection of miR-488-3p (magenta) and 403 
Cerox1 (green) in N2A cells.  Scale bar = 5 m.  A no probe control (Figure 5 – figure supplement 1D) 404 
indicated some background Fast Red signal (miRNA detection) localised to the nucleus, but no 405 
background for Alexa Fluor-488 (lncRNA detection). 406 
 407 
Cerox1 activity is mediated by miR-488-3p 408 
 409 
Our previous results showed that Cerox1 abundance modulates complex I activity and transcripts 410 
(Figs. 2-4) and that miR-488-3p has the greatest effect in decreasing Cerox1 transcript levels (Figure 411 
5E). To determine whether miR-488-3p modulates complex I transcript levels we overexpressed and 412 
inhibited miR-488-3p in N2A cells (Figure 6A,B). Results showed that miR-488-3p modulates these 413 
transcripts’ levels, with overexpression leading to a significant downregulation of all 12 Cerox1-414 
sensitive complex I transcripts (Figure 6A), whilst, conversely, miR-488-3p inhibition leads to 415 
increased expression for 10 of 12 transcripts, of which 4 (Ndufa2, Ndufb9, Ndufs4 and Ndufs1) were 416 
significantly increased (Figure 6B).  417 
 418 
To determine whether the single predicted miR-488-3p MRE in Cerox1 is required to exert its effects 419 
on complex I we created a Cerox1 transcript containing three mutated nucleotides within this MRE 420 
(Figure 6C). As expected for a bona fide MRE, these substitutions abrogated the ability of miR-488-421 
3p to destabilise Cerox1 transcript in a luciferase assay (Figure 6D).  Importantly, these substitutions 422 
also abolished the ability of Cerox1, when overexpressed, to elevate complex I transcript levels 423 
(Figure 6E), and to enhance complex I enzymatic activity (Figure 6F).  The latter observation is 424 
important because not all bona fide miRNA-transcript interactions are physiologically active (47).  425 
 426 
Finally, direct physical interaction between Cerox1 and miR-488-3p was confirmed by pulling-down 427 
transcripts with biotinylated miR-488-3p (Figure 6G). This experiment also identified 9 of 10 complex 428 
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I transcripts tested as direct targets of miR-488-3p binding. These included transcripts not predicted 429 
as containing a miR-488-3p MRE, as expected from the high false negative rate of MRE prediction 430 
algorithms (48-50). Also as expected, the two negative control transcripts, which are not responsive 431 
to Cerox1 transcript levels and have no predicted MREs for miR-488-3p, failed to bind miR-488-3p. 432 
 433 
 434 
 435 
Figure 6.  An intact miR-488-3p response element site is required for the effect of Cerox1 on 436 
complex I catalytic activity. (A) Overexpression of miR-488-3p knocks down all Cerox1-sensitive 437 
subunit transcripts.  Error bars s.e.m. (n = 3 biological replicates for control and overexpression of 438 
miR-488-3p).  2-sided t-test; ***P < 0.001, ** P < 0.01, * P < 0.05 (B) Inhibition of miR-488-3p 439 
increases the expression of most (10/12) target transcripts compared to the control. Error bars 440 
s.e.m. (n = 3 biological replicates for control and inhibition of miR-488-3p).  2-sided t-test; ** P < 441 
0.01, * P < 0.05. (C) Schematic of the predicted miR-488-3p miRNA recognition element in Cerox1.  442 
The interaction of miR-488-3p with Cerox1 is predicted to involve a 7mer-8m seed site, with the 443 
heptamer sequence of the seed being complementary to nucleotides 2-8 of the miRNA. Underlined 444 
residues indicate the location of the seed region mutation. (D) Luciferase destabilisation assay for 445 
both wildtype Cerox1 and Cerox1 mutated within the miR-488-3p MRE.  Error bars s.e.m. (n = 4 446 
biological replicates for each condition).  2-sided t-test; ** P < 0.01.  (E, F) Overexpression of Cerox1 447 
mutated within a single miR-488-3p MRE (E) failed to alter expression levels of complex I subunits 448 
that increase in expression with wild-type Cerox1 overexpression (error bars s.e.m, n = 3 biological 449 
replicates) and (F) failed to recapitulate the increase in complex I catalytic activity observed for the 450 
wildtype transcript.  Fold change of wildtype Cerox1 compared to the control is indicated on the left 451 
of panel E.  As expected, wildtype enzymatic activity was significantly different for complex I (F [2, 452 
21] = 4.944 P = 0.019).  A post-hoc Dunnett’s test indicated that the overexpression of wildtype 453 
Cerox1 resulted in significantly increased complex I activity, while the comparison of the Cerox1 miR-454 
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488-3p MRE mutant with the control was not significant. There was no significant difference in the 455 
activity of citrate synthase (F[2,21]=1.4, P = 0.28). n = 8 biological replicates. Significance levels, one-456 
way ANOVA, Dunnett’s post hoc test * P < 0.05, ns = not significant.  (G) Enrichment of 9 Cerox1 457 
sensitive transcripts that do not have predicted canonical 3’UTR miR-488-3p MREs using biotinylated 458 
miR-488-3p as bait as compared to the control biotinylated miRNA.  Error bars s.e.m. (n = 3 459 
biological replicates).  2-sided t-test; *** P < 0.001, ** P < 0.01, * P < 0.05, ns – not significant. 460 
 461 
 462 
Considered together, these findings indicate that: (i) Cerox1 can post-transcriptionally regulate 463 
OXPHOS enzymatic activity as a miRNA decoy, and (ii) of 12 miR-488-3p:Nduf transcript interactions 464 
that were investigated, all 12 are substantiated either by responsiveness to miR-488-3p through 465 
miRNA overexpression or inhibition (Figure 6A,B), or by direct interaction with a biotinylated miR-466 
488-3p mimic (Figure 6G). Consequently, our data demonstrates that miR-488-3p directly regulates 467 
the transcript levels of Cerox1 and at least 12 nuclear encoded mitochondrial complex I subunit 468 
genes (31% of all) and indirectly modulates complex I activity (Figure 6F) in N2A cells. 469 
 470 
Cerox1 is an evolutionarily conserved regulator of mitochondrial complex I activity 471 
Fewer than 20% of lncRNAs are conserved across mammalian evolution (51) and even for these 472 
functional conservation has rarely been investigated. In our final set of experiments we 473 
demonstrated that CEROX1, the orthologous human transcript, is functionally equivalent to mouse 474 
Cerox1 in regulating mitochondrial complex I activity. Similar to mouse Cerox1, human CEROX1 is 475 
highly expressed in brain tissue, is otherwise ubiquitously expressed (Supplementary Figure 1b), and 476 
is enriched in the cytoplasm of human embryonic kidney (HEK293T) cells (Figure 7A). CEROX1 is 477 
expressed in human tissues at unusually high levels: it occurs among the top 0.3% of all expressed 478 
lncRNAs (Figure 7B) and its average expression is higher than 87.5% of all protein coding genes (52).  479 
Its expression is highest within brain tissues, particularly within the basal ganglia and cortex (Figure 480 
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7C). 481 
 482 
Importantly, mitochondrial complexes’ I and III activities increased significantly following CEROX1 483 
overexpression in HEK293T cells (Figure 7D). CEROX1 overexpression had a greater effect on 484 
complex I activity than the mouse orthologous sequence and also increased the activity of complex 485 
III, rather than complex IV activity, in these cells.  In addition to these observed increases in enzyme 486 
activity, basal respiration increased by 35%, ATP-linked respiration increase by 31% and maximum 487 
uncoupled respiration increased by 31% (P = 0.02,  P = 0.04,  P = 0.01 respectively, 2-tailed Student’s 488 
t-test; Figure 7E).   The latter distinction could reflect the differences in miRNA pools between 489 
mouse and human cell lines and/or the presence of different MREs in the lncRNA and human 490 
OXPHOS transcripts.  491 
 492 
Strikingly, either reciprocal expression of mouse Cerox1 in human HEK293T cells or human CEROX1 493 
in mouse N2A cells, recapitulates the previously observed increase in complex I activity (Figure 7F). 494 
This effect of mouse Cerox1 overexpression in mouse N2A cells is greater than for human CEROX1 495 
overexpression in these cells. The role of both Cerox1 and CEROX1 in modulating the activity of 496 
mitochondrial complex I has thus been conserved over 90 million years since the last common 497 
ancestor of mouse and human. 498 
 499 
 500 
 501 
Figure 7. Human CEROX1 modulates complex I activity in mouse cells. (A) CEROX1 is enriched in the 502 
cytoplasm.  Error bars s.e.m.  n = 4 biological replicates.  (B) Relative levels of lncRNA (blue) and 503 
protein-coding gene (grey) expression across individuals and tissues in human. The black arrow 504 
indicates the expression level of CEROX1 in the set of 5161 lncRNAs. RPKM: reads per kilobase per 505 
million reads. (C) Average expression levels of CEROX1 in human tissues. Blue bars highlight 506 
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neurological tissues used to build the inset graph. The inset graphic represents the comparison of 507 
gene expression variation among individuals for neurological tissues: 1–Putamen, 2-Caudate 508 
nucleus, 3-Nucleus accumbens, 4–Cortex, 5-Substantia nigra, 6–Amygdala, 7–Hippocampus, 8-Spinal 509 
cord, 9-Anterior cingulate cortex, 10-Frontal cortex, 11–Hypothalamus, 12-Tibial nerve, 13–510 
Cerebellum, 14–Pituitary gland, 15-Cerebellar hemisphere. (D) OXPHOS enzyme activities in human 511 
HEK293 cells after 72 hours of CEROX1 overexpression. Overexpression of CEROX1 results in 512 
significant increases in the activities of complexes I (31% increase) and III (18% increase), with no 513 
significant change in other enzyme activities. n = 8 biological replicates. 2-sided t-test:  P < 0.05, 514 
ns=not significant.  (E) Oxygen consumption, as measured on a Seahorse XFe24 Analyzer, by HEK293T 515 
cells overexpressing CEROX1.  Top: normalised real time oxygen consumption rate in basal 516 
conditions and after sequential injections of oligomycin, FCCP and rotenone/antimycin A.  Bottom: 517 
changes in basal, ATP-linked and maximum uncoupled respiration respectively. Error bars s.e.m.  n = 518 
6 biological replicates.    (F) Reciprocal overexpression of mouse Cerox1 in human HEK293 cells or 519 
human CEROX1 in mouse N2A cells results in elevated complex I activity.  n = 8 biological replicates. 520 
2-sided t-test: *** P <0.001, ** P < 0.01, ns=not significant. 521 
 522 
DISCUSSION 523 
Cerox1 is the first evolutionarily conserved lncRNA to our knowledge that has been demonstrated 524 
experimentally to regulate mitochondrial energy metabolism.  Its principal location in N2A cells is in 525 
the cytoplasm (Figure 1F) where it post-transcriptionally regulates the levels of mitochondrial 526 
OXPHOS subunit transcripts and proteins by decoying for miRNAs (Supplementary Figure 5), most 527 
particularly miR-488-3p. This microRNA shares with Cerox1 an early eutherian origin and elevated 528 
expression in brain samples (41), and it previously was shown to alter mitochondrial dynamics in 529 
cancer cells (53).  Changes in Cerox1 abundance in vitro alter mitochondrial OXPHOS subunit 530 
transcript levels and, more importantly, elicit larger changes in their protein subunits levels, leading 531 
to unexpectedly large changes in mitochondrial complex I catalytic activity.  The observed changes in 532 
 22 
 
catalytic activity are in line with the degree of change seen in diseases exhibiting mitochondrial 533 
dysfunction (54-56). Overexpression of Cerox1 in N2A cells increases oxidative metabolism, halves 534 
cellular oxidative stress and enhances protection against the complex I inhibitor rotenone. The effect 535 
of Cerox1 on complex I subunit transcript levels can be explained by their sharing MREs with Cerox1, 536 
and subsequent competition for miRNA binding, most notably for miR-488-3p, which buffers the 537 
OXPHOS transcripts against miRNA-mediated repression.   538 
 539 
Multiple RNA transcripts have been experimentally shown to compete with mRNAs for binding to 540 
miRNAs, thereby freeing the protein coding mRNA from miRNA-mediated repression (57-62). It has 541 
been experimentally demonstrated that this miRNA:RNA regulatory crosstalk can initiate rapid co-542 
ordinate modulation of transcripts whose proteins participate within the same complex or process 543 
(62). Physiological relevance of this crosstalk mechanism remains incompletely understood. 544 
Furthermore, mathematical modelling (63-65) and experimental investigation (66, 67) of the 545 
dynamics and mechanism of endogenous transcript competition for miRNA binding have resulted in 546 
contrasting conclusions.  Current mathematical models do not take full account of miRNA 547 
properties, such as the repressive effect not being predictable from its cellular abundance (68), 548 
intracellular localisation such as at the rough ER (69), loading on the RNA-induced silencing complex 549 
(RISC) (Flores et al., 2014), or AGO2’s phosphorylation status within the RISC (Golden et al. 2017). 550 
The conclusions of experiments have also assumed that all miRNA target transcripts that contain the 551 
same number and affinity of miRNA binding sites are equivalent, that steady-state measurements 552 
are relevant to repression dynamics, and that observations for one miRNA in one experimental 553 
system are equally applicable to all others (70).  554 
 555 
Considered together, our lines of experimental evidence indicate that miRNA-mediated target 556 
competition by Cerox1 substantially perturbs a post-transcriptional gene regulatory network that 557 
includes at least 12 complex I subunit transcripts.  This is consistent with the expression level of miR-558 
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488-3p (71) and the high in vivo expression of both Cerox1 and OXPHOS transcripts (29, 72).  Human 559 
CEROX1 levels, for example, exceed those of all complex I subunit transcripts (those in Figure 6a) in 560 
both newly-formed and myelinating oligodendrocytes (73).  Cerox1 could maintain OXPHOS 561 
homeostasis in cells with sustained high metabolic activity and high energy requirements.  Such cells 562 
occur in the central nervous system, in which Cerox1 levels are high (74), and in haematopoiesis 563 
where depletion of Cerox1 results in decreased expression of OXPHOS components and in defects 564 
during differentiation of the committed myeloid progenitor population (26) 565 
 566 
Our experiments demonstrate that post-transcriptional regulation of a subset of complex I subunits 567 
by Cerox1 leads to elevated oxygen consumption.  How consumption increases when there is a 568 
higher abundance of only a subset of OXPHOS transcripts remains unclear.  However, this 569 
phenomenon has been observed previously in mouse dopaminergic neurons (36) and primary 570 
mouse embryonic fibroblasts and pinnal tissues (35).   Our observation of increased enzymatic 571 
activity may relate to the formation, by the complexes of the respiratory chain, of higher order 572 
supercomplexes (75, 76).  Alternatively,  the observed increases in OXPHOS activity may reflect some 573 
subunits of the complex I holo-enzyme (including NDUFS3 and NDUFA2) being present as a 574 
monomer pool and therefore being available for direct exchange without integration into assembly 575 
intermediates (3). This monomer pool facilitates the rapid swapping out of oxidatively damaged 576 
complex I subunits (3). It is thus possible that Cerox1-mediated expansion of the monomer pool 577 
thereby improves complex I catalysis efficiency (Figure 8).  However, we note that overexpression 578 
of Cerox1 results in the differential expression of 286 genes, most (83%) of which are upregulated. 579 
These genes’ transcripts will be both the targets of miR-488-3p decoying by Cerox1 (Figure 6) and 580 
those whose upregulation is secondary to Cerox1 (and miR-488-3p) mediated effects, for example 581 
relating to the observed changes in cellular metabolism and proliferation (Figure 2 – figure 582 
supplement 1I, J, K). 583 
 584 
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Figure 8.  Proposed model for Cerox1 as a post-transcriptional regulator of mitochondrial protein 585 
production and energy metabolism. In this model, Cerox1 (A) post-transcriptionally maintains energy 586 
metabolism homeostasis through buffering the stable ETC transcripts against miRNA-mediated gene 587 
silencing. Overexpression of Cerox1 (B) leads to a depletion of the pool of miRNAs that bind ETC 588 
transcripts, and therefore a decrease in miRNA mediated gene silencing of the ETC protein-coding 589 
transcripts. This has two subsequent effects: 1) a further accumulation of ETC protein coding 590 
transcripts, and 2) an increase in the overall translation of ETC subunit proteins owing to decreased 591 
miRNA binding to ETC transcripts. More rapid replenishment by undamaged subunits in 592 
mitochondrial complex I, leads to increased efficiency of complex I activity and hence an increase in 593 
overall oxygen consumption of the ETC. 594 
 595 
 596 
 597 
More efficient ETC enzymatic activity might be relevant to mitochondrial dysfunction, a feature of 598 
many disorders that often manifests as decreases in the catalytic activities of particular 599 
mitochondrial complexes. A decrease in catalytic activity can result in elevated ROS production, 600 
leading to oxidative damage of lipids, DNA, and proteins, with OXPHOS complexes themselves being 601 
particularly susceptible to such damage (77). Parkinson’s and Alzheimer’s diseases both feature 602 
pathophysiology associated with oxidative damage resulting from increased ROS production and a 603 
cellular energy deficit associated with decreased complex I and IV activities (a reduction of 30% and 604 
40%, respectively) (54, 78, 79).  A deficiency in complexes II, III and to a lesser extent complex IV, has 605 
also been described in Huntington disease (80). Currently no effective treatments exist that help to 606 
restore mitochondrial function despite demonstration that a 20% increase in complex I activity 607 
protects mouse midbrain dopaminergic neurons against MPP+, a complex I inhibitor and a chemical 608 
model of Parkinson’s disease (36). We note that highest expression of CEROX1 occurs primarily in 609 
the basal ganglia (Figure 7C inset) regions of which are specifically vulnerable to the progressive 610 
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neurological disorders Parkinson’s (substantia nigra pars compacta) and Huntington’s diseases 611 
(striatum: caudate and putamen).  The specific energy demands of these neurons may make them 612 
particularly susceptible to damage due to an energy deficit. For instance, the dopaminergic neurons 613 
of the substantia nigra, which are especially sensitive to degeneration in Parkinson’s disease, have 614 
unusually large axonal arbours that require tight regulation of cellular energy to maintain (81).  In 615 
addition, the medium spiny neurons of the striatum, which preferentially degenerate in Huntington 616 
disease, exhibit a high degree of axonal collateralization – a morphological trait which implies high 617 
cellular energy consumption for its maintenance (82) – therefore causing these cells to be vulnerable 618 
to decreased cellular ATP production. CEROX1’s ability to increase mitochondrial complex I activity 619 
might be recapitulated pharmacologically to restore mitochondrial function, as an exemplar of 620 
therapeutic upregulation of gene expression (83).  621 
 622 
MATERIALS AND METHODS 623 
Key Resources table 624 
 625 
 626 
Gene expression profiling  627 
Reagent type (species) or resource Designation Source or reference Identifiers Additional information
gene (Mus musculus ) Cerox1 NA
AK079380; 2810468N07Rik; 
ENSMUST00000163493
gene (Homo sapiens ) CEROX1 NA BC098409; RP11-161M6.2; ENST00000562570
cell line (Mus musculus ) N2A (mouse neuroblastoma cells)
European Collection of Authenicated Cell 
Cultures (ECACC) RRID: CVCL_0470; ECACC: 89121404
cell line (Homo sapiens ) HEK293T (human embryonic kidney cells)
European Collection of Authenicated Cell 
Cultures (ECACC) RRID:  CVCL_0063; ECACC 12022001
transfected construct (Mus musculus  and 
Homo sapiens )
pCAG-GFP
https://www.addgene.org/89684/ RRID:Addgene_89684
This backbone was modified for 
overexpression of Cerox1, Cerox1 MRE 
mutants and CEROX1
transfected construct (Mus musculus ) BLOCK-it U6 shRNA expression construct Invitrogen K494500
transfected construct (Mus musculus ) BLOCK-iT™ Pol II miR RNAi expression vector Invitrogen K493600
antibody anti-NDUFS1, rabbit monoclonal Abcam RRID: AB_2687932; ab169540 Overnight, 4 degrees (1:30,000)
anti-NDUFS3, mouse monoclonal Abcam RRID:AB_10861972; ab110246 Overnight, 4 degrees, 0.15 mg/ml
anti-alpha tubulin, mouse monoclonal Abcam RRID:AB_2241126; ab7291 Overnight, 4 degrees (1:30,000)
goat anti-rabbit HRP, goat polyclonal Invitrogen RRID:AB_2536530; G-21234 Room temperature, 1 hr (1:30,000)
goat anti-mouse HRP, goat polyclonal Dako RRID:AB_2617137; P0447 Room temperature, 1hr (1:3,000)
recombinant DNA reagent Fugene6 Promega E2691
commercial assay or kit Amplex™ Red Hydrogen Peroxide/Peroxidase Assay KitThermofisher A22188
OxyBlot protein oxidation detetion kit Merck Millipore S7150
QuantiGene ViewRNA miRNA ISH cell assay kit Affymetrix QVCM0001
chemical compound, drug Rotenone Sigma Aldrich R8875-5G
Antimycin A Sigma Aldrich A8674-25MG
Sodium Azide Sigma Aldrich S8032-25G 
Oligomycin Sigma Aldrich 75351-5MG
NADH (reduced) Sigma Aldrich N8129-1G
coenzyme Q Sigma Aldrich C7956-2mg
Fatty acid free albumin Sigma Aldrich A8806-1G
Sodium succinate Sigma Aldrich S5047-100G
Dichlorophenolindophenol (DCPIP) Sigma Aldrich 33125-5G-R
Decylubiquinone Sigma Aldrich D7911-10mg 
cytochrome c Sigma Aldrich C7752
Carbonyl cyanide 4(trifluoromethoxy)phenylhydrazone Sigma Aldrich C2920-10mg
miRNA inhibitors Ambion 4464084
miRCURY LNA biotinylated miRNAs Exiqon 339178
software, algorithm TargetScan v7.0 Argawal et al., (2015) RRID: SCR_010845;  DOI: 10.7554/eLife.05005
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The lncRNA transcripts were assessed for coding potential using the coding potential calculator (84), 628 
PhyloCSF (85) and by mining proteomics and small open reading frame resources for evidence of 629 
translation (86-88).  A lack of protein-coding potential for human CEROX1 (also known as RP11-630 
161M6.2, LMF1-3) is supported by a variety of computational and proteomic data summarised in 631 
LNCipedia (89).  Expression data from somite-staged mouse embryos were acquired from 632 
ArrayExpress (E-ERAD-401 - Strand-specific RNA-seq of somite-staged second generation 633 
genotypically wild-type embryos of mixed G0 lineage from the Mouse Genetics Project/DMDD).  634 
Genome wide associations were performed on the UK Biobank data as described in (90) using data 635 
from up to 452,264 individuals. 636 
 637 
5’ and 3’ ends of the mouse and human lncRNA transcripts were confirmed by 5’ and 3’ RACE using 638 
the GeneRacer™ Kit (Invitrogen) according to the manufacturer’s instructions.  Total RNA from 639 
twenty normal human tissues (adipose, bladder, brain, cervix, colon, oesophagus, heart, kidney, 640 
liver, lung, ovary, placenta, prostate, skeletal muscle, small intestine, spleen, testes, thymus, thyroid 641 
and trachea) were obtained from FirstChoice® Human Total RNA Survey Panel (Invitrogen).  Total 642 
RNA from twelve mouse tissues (bladder, brain, colon, heart, kidney, liver, pancreas, skeletal muscle, 643 
small intestine, stomach and testis) were obtained from Mouse Tissue Total RNA Panel (Amsbio).  644 
RNA from cell lines was extracted using the RNeasy mini kit (Qiagen) according to the 645 
manufacturer’s instructions, using the optional on column DNase digest.  cDNA synthesis for all 646 
samples was performed on 1 g of total RNA using a QuantiTect Reverse Transcription kit (Qiagen) 647 
according to the manufacturer’s instructions.  RNA was extracted from samples used for the 648 
detection of miRNAs using the miRNeasy mini kit (Qiagen) according to the manufacturer’s 649 
instructions (with on column DNase digest).  All RNA samples were quantified using the 260/280 nm 650 
absorbance ratio, and RNA quality assessed using a Tapestation (Agilent).  RNA samples with an RNA 651 
integrity number (RIN) >8.5 were reverse transcribed.  1 g of total RNA from the miRNA samples 652 
were reverse transcribed using the NCode VILO miRNA cDNA synthesis kit.  Expression levels were 653 
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determined by real-time quantitative PCR, using SYBR® Green Master Mix (Applied Biosystems) and 654 
standard cycling parameters (95oC 10 min; 40 cycles 95oC 15s, 60oC 1 min) followed by a melt curve 655 
using a StepOne™  thermal cycler (Applied Biosystems).  All amplification reactions were performed 656 
in triplicate using gene specific primers.  Multiple reference genes were assessed for lack of 657 
variability using geNorm (91). Human expression data were normalised to TUBA1A and POLR2A, 658 
whilst mouse expression data were normalised to Tbp and Polr2a. Oligonucleotide sequences are 659 
provided in supplementary file 4. 660 
 661 
Tissue culture and flow cytometry 662 
Mouse Neuro-2a neuroblastoma cells (N2A; RRID: CVCL_0470; ECACC 89121404) and human 663 
embryonic kidney (HEK293T; RRID:  CVCL_0063; ECACC 12022001) were sourced from the European 664 
authenticated cell culture collection.  HEK293T cells were confirmed by STR profiling and cell lines 665 
were tested monthly for mycoplasma contamination. Cells were grown at 37OC in a humidified 666 
incubator supplemented with 5% CO2.  Both cell lines were grown in Dulbecco’s modified Eagle 667 
medium containing penicillin/streptomycin (100 U/ml, 100 ug/ml respectively) and 10% fetal calf 668 
serum.  Cells were seeded at the following densities:  6 well dish, 0.3 x 106; 48 well dish, 0.2 x 104; 669 
T75 flask 2.1 x 106.   We had three reasons for the choice of HEK293T cells for this experiment. First, 670 
they are of neural crest ectodermal origin (92) and therefore have a number of neural cell line 671 
characteristics in that they express neuronal markers (Shaw, Morse, Ararat, & Graham, 2002). 672 
Second, they are in use as a cell culture model for neurodegenerative diseases such as Parkinson’s 673 
disease (93, 94). Third, HEK293T cells are a widely used cell line to interrogate human mitochondrial 674 
biochemistry, and exhibit complex I dependent respiration (95).  Mouse embryonic stem cells and 675 
dicer knock-out embryonic stem cells were maintained as described previously (40). Cells were 676 
counted using standard haemocytometry.  For flow cytometry the cells were harvested by 677 
trypsinization, washed twice with PBS and fixed in 70% ethanol (filtered, -20oC).  The cell suspension 678 
was incubated at 4oC for 10 min and the cells pelleted, treated with 40 g/ml RNase A and 679 
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propidium iodide (40 g/ml) for 30 min at room temperature.  Cells were analysed using a 680 
FACSCalibur (BD-Biosciences) flow cytometer.   681 
 682 
Fluorescent in situ hybridization of miRNA and lncRNA, cellular fractionation and RNA turnover 683 
Branched chain DNA probes to Cerox1, Malat1 and mmu-miR-488-3p were sourced from Affymetrix.   684 
The protocol was preformed according to the manufacturer’s instructions using the QuantiGene 685 
ViewRNA miRNA ISH cell assay kit (QVCM0001) for adherent cells.  The following parameters were 686 
optimised:  cells were fixed in 4% formaldehyde for 45 minutes and a 1:2000 dilution of the protease 687 
was optimal for the N2A cells.  Cells were imaged using an Andor Dragonfly confocal inverted 688 
microscope, and images acquired using an Andor Zyla 4.2 plus camera. 689 
Cells were fractionated into nuclear and cytoplasmic fractions in order to determine the 690 
predominant cellular localization of lncRNA transcripts.  Briefly, approximately 2.8 x 106 cells were 691 
collected by trypsinization, washed three times in PBS and pelleted at 1000 g for 5 min at 4oC.  The 692 
cell pellet was resuspended in 5 volumes of lysis buffer (10 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 10 693 
mM NaCl, 5 mM EGTA, 0.05% NP40, and protease inhibitors [Roche, complete mini]) and incubated 694 
on ice for 15 min.  Lysed cells were then centrifuged at 2000 g for 10 min at 4oC, and the supernatant 695 
collected as the cytoplasmic fraction.   Nuclei were washed three times in nuclei wash buffer (10 mM 696 
HEPES, pH 6.8, 300 mM sucrose, 3 mM MgCl2,  25 mM NaCl, 1 mM EGTA), and pelleted by 697 
centrifugation at 400 g, 1 min at 4oC.  Nuclei were extracted by resuspension of the nuclei pellet in 698 
200 l of nuclei wash buffer containing 0.5% Triton X-100 and 700 units/ml of DNase I and incubated 699 
on ice for 30 mins. Nucleoplasm fractions were collected by centrifugation at 17 000g for 20 min at 700 
4oC.     RNA was extracted as described above, and RNA samples with RIN values >9.0 used to 701 
determine transcript localisation. 702 
 703 
To determine the stability of the lncRNA transcripts, cells were cultured to ~50 % confluency and 704 
then transcription was inhibited by the addition of 10 g/ml actinomycin D (Sigma) in DMSO.  705 
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Control cells were treated with equivalent volumes of DMSO.  Transcriptional inhibition of the N2A 706 
cells was conducted for 16 hours with samples harvested at 0 hrs, 30 mins, 1 hr, 2 hrs, 4 hrs, 8 hrs 707 
and 16 hrs.  RNA samples for fractionation and turnover experiments were collected in Trizol 708 
(Invitrogen) and RNA purified and DNAse treated using the RNeasy mini kit (Qiagen).   Reverse 709 
transcription for cellular localisation and turnover experiments was performed as described earlier. 710 
 711 
Constructs and biotinylated miRNAs 712 
The 5’ and 3’ ends of Cerox1 were identified by 5’ and 3’ RACE using the GeneRacer™ Kit (Invitrogen) 713 
according to manufacturer’s instructions.  As an overexpression/transfection control the pCAG-EGFP 714 
backbone  was used (RRID:Addgene_89684).  The EGFP was removed from this backbone, and all full 715 
length lncRNAs were cloned into the pCAG backbone.  For cloning into the pCAGs vector, PCR 716 
primers modified to contain the cloning sites BglII and XhoI sites were used to amplify the full length 717 
mouse Cerox1, whilst human CEROX1 and the mouse 5x MRE mutant were synthesised by Biomatik 718 
(Cambridge, Ontario), and also contained BglII and XhoI sites at the 5’ and 3’ ends respectively.  All 719 
other MRE mutants were produced using overlapping PCR site directed mutagenesis to mutate 3 720 
bases of the miRNA seed region.  All purified products were ligated into the prepared backbone and 721 
then transformed by heat shock into chemically competent DH5, and plated on selective media.  722 
All constructs were confirmed by sequencing.  Short hairpin RNAs specific to the transcripts were 723 
designed using a combination of the RNAi design tool (Invitrogen) and the siRNA selection program 724 
from the Whitehead Institute (96).  Six pairs of shRNA oligos to the target genes and β-galactosidase 725 
control oligos were annealed to create double-stranded oligos and cloned into the BLOCK-iT™ U6 726 
vector (Invitrogen), according to the manufacturer’s instructions. miRNA expression constructs were 727 
generated and cloned into the BLOCK-iT™ Pol II miR RNAi expression vector (Invitrogen) according to 728 
the manufacturer’s instructions.  miRNA inhibitors were sourced from Ambion and used according to 729 
manufacturer’s instructions.   730 
 731 
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Transfection efficiency was initially assessed by FACS, and the optimised transfection protocol used 732 
for all further assays (6:1 transfection reagent to DNA ratio). One day prior to transfection cells were 733 
either seeded in 6 well dishes (0.3 x 106 cells/well), or in T75 flasks (2.1 x 106 cells/flask).  Twenty-734 
four hours later cells in 6 well dishes were transfected with 1 g of shRNA, miRNA or overexpression 735 
construct and their respective control constructs using FuGENE® 6 (Promega) according to the 736 
manufacturer’s guidelines.  Cells in T75 flasks were transfected with 8 g of experimental or control 737 
constructs. Transfected cells were grown for 48 hours under standard conditions, and then 738 
harvested for either gene expression studies or biochemical characterisation. Efficacy of the 739 
overexpression and silencing constructs was determined by real-time quantitative PCR.   740 
 741 
Transcripts for the luciferase destabilisation assays were cloned into the pmirGLO miRNA target 742 
expression vector (Promega) and assayed using the dual-luciferase® reporter assay system 743 
(Promega).  miRCURY LNA biotinylated miRNAs (mmu-miR-488-3p and mmu-negative control 4) 744 
were purchased from Exiqon, and  direct mRNA-miRNA  interactions were detected using a modified 745 
version of (97) and enrichment of targets was detected by qPCR. 746 
 747 
Computational techniques 748 
MREs were predicted using TargetScan v7.0 (RRID: SCR_010845) in either the 3’UTR (longest 749 
annotated UTR, ENSEMBL build 70; RRID: SCR_002344) or the full length transcript of protein coding 750 
genes, and across the entire transcript for lncRNAs. The average expression across 46 human tissues 751 
and individuals according to the Pilot 1 data from the GTEx Consortium (RRID:SCR_013042; 98) was 752 
computed for both protein-coding genes and intergenic lncRNAs from the Ensembl release 75 753 
annotation (99).  We used the normalized number of CAGE tags across 399 mouse cells and tissues 754 
from the FANTOM5 Consortium (http://fantom.gsc.riken.jp)(100) as an approximation of expression 755 
levels for protein-coding genes and intergenic lncRNAs from the Ensembl release 75 annotation. If 756 
multiple promoters were associated with a gene, we selected the promoter with the highest average 757 
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tag number.  Conserved sequence blocks in the lncRNA sequences were identified using LALIGN 758 
(101).  759 
 760 
Microarray analysis 761 
Microarray analysis was performed on 16 samples (four overexpression/four overexpression 762 
controls; four knock-down/four knock-down controls), and hybridizations were performed by the 763 
OXION array facility (University of Oxford).  Data were analysed using the web-based Bioconductor 764 
interface, CARMAweb (102). Differentially expressed genes (Bonferroni corrected P-value <0.05) 765 
were identified between mouse lncRNA overexpression and control cells using Limma from the 766 
Bioconductor package between the experimental samples and the respective controls.   Microarray 767 
data are accessible through ArrayExpress, accession E-MATB-6792. 768 
 769 
Extraction of metabolites and liquid chromatography – mass spectrometry (LC-MS) 770 
Metabolites were extracted from 6-well plates by washing individual wells with ice-cold PBS and 771 
addition of cold extraction buffer (50% methanol, 30% acetonitrile, 20% water solution at -20°C or 772 
lower). Extracts were clarified and stored at -80°C until required. LC-MS was carried out using a 100 773 
mm x 4.6 mm ZIC-pHILIC column (Merck-Millipore) using a Thermo Ultimate 3000 HPLC inline with a 774 
Q Exactive mass spectrometer. A 32 min gradient was developed over the column from 10% buffer A 775 
(20 mM ammonium carbonate), 90% buffer B (acetonitrile) to 95% buffer A, 5% buffer B. 10 μl of 776 
metabolite extract was applied to the column equilibrated in 5% buffer A, 95% buffer B. Q Exactive 777 
data were acquired with polarity switching and standard ESI source and spectrometer settings were 778 
applied (typical scan range 75-1050). Metabolites were identified based upon m/z values and 779 
retention time matching to standards. Quantitation of metabolites was carried out using AssayR 780 
(103). Data were normalised using levels of 9 essential amino acids (histidine, isoleucine, leucine, 781 
lysine, methionine, phenylalanine, threonine, tryptophan, valine), and errors propagated, in order to 782 
account for cell count differences. 783 
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 784 
Western blots 785 
Total protein was quantified using a BCA protein assay kit (Pierce).  10 g of protein was loaded per 786 
well, and samples were separated on 12% SDS-PAGE gels in Tris-glycine running buffer (25 mM Tris, 787 
192 mM glycine, 0.1% SDS).  Proteins were then electroblotted onto PVDF membrane (40V, 3 hrs) in 788 
transfer buffer (25 mM Tris-HCl, 192 mM glycine, 20% methanol), the membrane blocked in TBS-T 789 
(50 mM Tris-HCl, 150 mM NaCl, 0.1% Tween 20) with 5% non–fat milk powder for 1 hour.  The 790 
membrane was incubated with primary antibodies overnight at 4oC with the following dilutions:  791 
anti-NDUFS1 (RRID: AB_2687932; rabbit monoclonal, ab169540, 1:30,000), anti-NDUFS3 792 
(RRID:AB_10861972; mouse monoclonal, 0.15 mg/ml, ab110246), or anti-alpha tubulin loading 793 
control (RRID: AB_2241126; mouse monoclonal, ab7291, 1:30,000).   Following incubation with the 794 
primary antibodies, blots were washed 3 x 5 min, and 2 x 15 mins in TBS-T and incubated with the 795 
appropriate secondary antibody for 1 hour at room temperature: goat anti-rabbit HRP 796 
(RRID:AB_2536530; Invitrogen G-21234) 1:30,000; goat anti-mouse HRP (RRID:AB_2617137; Dako 797 
P0447) 1:3,000.  After secondary antibody incubations, blots were washed and proteins of interested 798 
detected using ECL prime chemiluminescent detection reagent (GE Healthcare) and the blots imaged 799 
using an ImageQuant LAS 4000 (GE Healthcare).  Signals were normalised to the loading control 800 
using ImageJ (104). 801 
 802 
Oxidative phosphorylation enzyme assays and oxygen consumption 803 
Cell lysates were prepared 48 hours post-transfection, by harvesting cells by trypsinisation, washing 804 
three times in ice cold phosphate buffered saline followed by centrifugation to pellet the cells (2 805 
mins, 1000 g).  Cell pellets were resuspended to homogeneity in KME buffer (100 mM KCl, 50 mM 806 
MOPS, 0.5 mM EGTA, pH 7.4) and protein concentrations were determined using a BCA protein 807 
assay detection kit (Pierce).  Cell lysates were flash frozen in liquid nitrogen, and freeze-thawed 808 
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three times prior to assay.  300-500 g of cell lysate was added per assay, and assays were 809 
normalised to the total amount of protein added.   810 
 811 
All assays were performed using a Shimadzu UV-1800 spectrophotometer, absorbance readings 812 
were taken every second and all samples were measured in duplicate.  Activity of complex I (CI, 813 
NADH:ubiquinone oxidoreductase) was determined by measuring the oxidation of NADH to NAD+ at 814 
340 nm at 30oC in an assay mixture containing 25 mM potassium phosphate buffer (pH 7.2), 5 mM 815 
MgCl2, 2.5 mg/ml fatty acid free albumin, 0.13 mM NADH, 65 M coenzyme Q and 2 g/ml antimycin 816 
A.  The decrease in absorbance was measured for 3 mins, after which rotenone was added to a final 817 
concentration of 10 M and the absorbance measured for a further 2 mins.  The specific complex I 818 
rate was calculated as the rotenone-sensitive rate minus the rotenone-insensitive rate.  Complex II 819 
(CII, succinate dehydrogenase) activity was determined by measuring the oxidation of DCPIP at 600 820 
nm at 30oC.  Lysates were added to an assay mixture containing 25 mM potassium phosphate buffer 821 
(pH 7.2) and 2 mM sodium succinate and incubated at 30oC for 10 mins, after which the following 822 
components were added, 2 g/ml antimycin A, 2 g/ml rotenone, 50 M DCPIP and the decrease in 823 
absorbance was measured for 2 mins.  Complex III (CIII, Ubiquinol:cytochrome c oxidoreductase) 824 
activity was determined by measuring the oxidation of decylubiquinol, with cytochrome c as the 825 
electron acceptor at 550nm.  The assay cuvettes contained 25 mM potassium phosphate buffer (pH 826 
7.2), 3 mM sodium azide, 10 mM rotenone and 50 M oxidized cytochrome c.  Decylubiquinol was 827 
synthesized by acidifying decylubiquinone (10mM) with HCl (6M) and reducing the quinine with 828 
sodium borohydride. After the addition of 35 M decylubiquinol, the increase in absorbance was 829 
measured for 2 mins.  Activity of Complex IV (CIV, cytochrome c oxidase) was measured by 830 
monitoring the oxidation of cytochrome c at 550 nm, 30oC for 3 min.  A 0.83 mM solution of reduced 831 
cytochrome c was prepared by dissolving 100 mg of cytochrome c in 10 ml of potassium phosphate 832 
buffer, and adding sodium ascorbate to a final concentration of 5 mM.  The resulting solution was 833 
added into SnakeSkin dialysis tubing (7 kDa molecular weight cutoff, Thermo Scientific) and dialyzed 834 
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against potassium phosphate buffer, with three changes, at 4oC for 24 hrs.  The redox state of the 835 
cytochrome c was assessed by evaluating the absorbance spectra from 500-600 nm.  The assay 836 
buffer contained 25 mM potassium phosphate buffer (pH 7.0) and 50 M reduced cytochrome c.  837 
The decrease in absorbance at 550 nm was recorded for 3 mins.   As a control the enzymatic activity 838 
of the tricarboxylic acid cycle enzyme, citrate synthase  (CS) was assayed at 412 nm at 30oC in a 839 
buffer containing 100 mM Tris-HCl (pH 8.0), 100 M DTNB (5,5-dithiobis[2-nitrobenzoic acid]), 50 840 
M acetyl coenzyme A, 0.1% (w/v) Triton X-100 and 250 M oxaloacetate.  The increase in 841 
absorbance was monitored for 2 mins.   842 
 843 
The following extinction coefficients were applied:  complex I (CI),  = 6220 M-1 cm-1, CII,  = 21,000 844 
M-1 cm-1; CIII,   =  19,100 M-1 cm-1; CIV,  = 21,840 M-1 cm-1 (the difference between reduced and 845 
oxidised cytochrome c at 550 nm); CS,  = 13,600 mM-1 cm-1. 846 
 847 
Cellular oxygen consumption rate was determined using the Seahorse XFe24 Analyzer (Agilent).  Cells 848 
were plated on poly-L-lysine coated XFe24 microplates at 50,000 cells per well and incubated at 37oC 849 
and 5% CO2 for 24 hrs.  Cells were transfected with an overexpression (pCAG-Cerox1 or pCAG-850 
CEROX1) or the Cerox1 shRNA silencing construct and assayed 24-36 hrs later.  Cells were washed 851 
three times with Seahorse Assay media (Agilent), supplemented with 10mM glucose and 2mM 852 
pyruvate. After 30 minutes of pre-incubation in a non-CO2 37°C incubator, cells were entered into 853 
the analyser for oxygen consumption rate measurements. After basal respiration measurements, 1 854 
μM of oligomycin was injected to inhibit ATP synthase, then 0.2 μM of carbonyl cyanide 4-855 
(trifluoromethoxy)phenylhydrazone (FCCP) was injected to uncouple respiration.  Finally 1 μM each 856 
of rotenone and antimycin A were injected to inhibit complex I and complex III respectively. Data 857 
was normalised to total cellular protein content using the sulforhodamine B assay (105).  Basal 858 
respiration, ATP linked respiration and maximum uncoupled respiration were calculated from the 859 
normalised data using the Agilent Seahorse XF calculation guidelines.  Briefly, basal respiration = 860 
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measurement 3 (last rate measurement before oligomycin injection) – measurement 10 (minimum 861 
respiration after injection of rotenone/antimycin A); ATP-linked respiration = measurement 3 – 862 
measurement 4 (minimum rate measurement after oligomycin injection); maximum uncoupled 863 
respiration = measurement 7 (maximum rate after FCCP injection) – measurement 10.  864 
 865 
Oxidative stress measurements 866 
Hydrogen peroxide production was assessed as a marker of reactive oxygen species generation using 867 
the fluorescent indicator Amplex Red (10 M, Invitrogen) in combination with horseradish 868 
peroxidise (0.1 units ml-1).  Total amount of H2O2 produced was normalised to mg of protein added. 869 
Protein carbonylation was assessed using the OxyBlot protein oxidation detection kit (Merck 870 
Millipore), and differential carbonylation was assessed by densitometry.  The cell stress assay was 871 
performed on cells seeded in 48 well plates, and assayed 12 hours later by the addition of (final 872 
concentration):  rotenone (5 M), malonate (40 M), antimycin A (500 M), oligomycin (500 M), 873 
sodium azide (3 mM), NaCl (300 mM), CaCl2 (5.4 mM).  Cells were heat shocked at 42
oC and UV 874 
irradiated using a Stratlinker UV Crosslinker for 10 minutes (2.4 J cm-2).  Cell viability was assessed by 875 
the addition of Alamar Blue (Invitrogen) according to the manufacturer’s instructions.   876 
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Figure supplements 1136 
 1137 
Figure 1 – figure supplement 1 1138 
Transcript characterisation.  (A) PhyloCSF tracks for mouse Cerox1 and Sox8 and human CEROX1 and 1139 
SOX8. (B) Expression of Cerox1 (i) and Sox8 (ii) in the adult mouse subventricular zone.  Cerox1 1140 
expression is particularly pronounced in oligodendrocyte precursors (COPs), myelin forming 1141 
oligodendrocytes (MFOLs types 1 and 2) and in myelinating oligodendrocytes (MOLs). Data from the 1142 
SVZ Cell Atlas: https://shiny.mdc-berlin.de/SVZapp/.  Tissue profiling of (C) mouse Cerox1 or (D) 1143 
human CEROX1 transcript levels by quantitative PCR. (E) rs3809674 is an eQTL for CEROX1 and 1144 
LMF1.  The largest normalised effect size is for CEROX1 in the opposite direction to LMF1 in the 1145 
cortex (-0.830  and 0.778 respectively). In the cortex LMF1 is expressed at levels ten times lower 1146 
than CEROX1.    (F) Expression levels inferred from FANTOM promoter atlas CAGE tag data for two 1147 
separate Cerox1 transcriptional start sites. The minor ‘long’ isoform corresponds to NR_045176, 1148 
whereas the major ‘short’ isoform corresponds to AK079380, which is referred to here as Cerox1. 1149 
Errors bars s.d. on samples with two or more biological samples. (G) Quantitative PCR confirmation 1150 
of the transcription of two isoforms. Cerox1 is the dominant isoform, with NR_045176 being 10-fold 1151 
more lowly expressed and is only detectable in brain tissue and N2A cells. (H) To measure the 1152 
transcript turnover of Cerox1 we inhibited transcription in N2A cells by the addition of the 1153 
transcriptional inhibitor actinomycin D, and measured the transcript half-life over a period of four 1154 
hours. Following transcriptional inhibition the remaining transcript was measured by qPCR relative 1155 
to time matched untreated control cells over a period of 4 hours. Transcripts ATP5e and myc were 1156 
included as controls for known long (>8h) and short (<30 min) half-lives respectively. Errors s.d. (n = 1157 
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3 biological replicates).   (I) qPCR analysis of sucrose gradient fractions to assess the distribution of 1158 
Cerox1 and Gapdh transcripts within ribosomal fractions.  n = 3, error bars s.e.m. 1159 
 1160 
 1161 
Figure 2 – figure supplement 2 1162 
(A) Fold-change in Cerox1 level following treatment with each of twelve unique shRNAs.  (B) CRISPR 1163 
activation and inhibition of the divergent Cerox1-Sox8 promoter. (C) Overexpression and sh92-1164 
mediated knockdown of Cerox1 have no significant effect on expression of its neighbouring protein 1165 
coding gene, Sox8 or the downstream gene, Lmf1. (D) qPCR validation of the expression increase in 1166 
OXPHOS subunit transcripts indicated by microarray technology. As significant fold changes in gene 1167 
expression from the microarray data were typically < 1.8 fold, we applied an arbitrary threshold of 1168 
1.4 fold change in expression for qPCR experiments (2-sided t-test; ** P < 0.01, * P < 0.05, ns = not 1169 
significant). Errors bars s.e.m. (n = 3 biological replicates). (E) Knockdown of Cerox1 with shRNA92 1170 
led to significant decreases in 3 complex I subunit transcripts (Ndufab1, Ndufs3 and Ndufs1) as 1171 
measured by qPCR (errors s.e.m., n = 3 biological replicates). (F) Knockdown of Cerox1 with 1172 
shRNA1159 also resulted in significant decreases in these transcripts (Ndufab1, Ndufs3 and Ndufs1) 1173 
as well as Ndufs6 (errors s.e.m., n = 4 biological replicates).   (G) Protein half-lives obtained from 1174 
mouse, human and rat primary cells and cell lines (27-29).  Blue dots represent Cerox1-sensitive 1175 
complex I subunits (if present in the dataset).  In the majority of cases, half-lives of these proteins 1176 
exceed the median half-life.  (H)  mRNA half-lives from mouse and human cell lines (29-32).  Orange 1177 
dots represent Cerox1-sensitive complex I subunits (if present in the dataset).  As for the protein 1178 
data, in most cases these transcripts have half-lives that exceed the median mRNA half-life.  (I) 1179 
Overexpression of Cerox1 slows cell growth. Counting of cells previously seeded to the same density 1180 
(0.1 x 106 cells/well) 48 hours post transfection demonstrated that there were 45% fewer cells in 1181 
wells overexpressing Cerox1 (P = 0.02, two-tailed Student’s t-test, errors s.d., n = 6). (J) The 1182 
percentage of viable cells was not significantly different in Cerox1 overexpression and control cells (p 1183 
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= 0.1, two-tailed Student’s t-test, errors s.d., n = 6). (K) N2A cells overexpressing control and Cerox1 1184 
were stained with propidium iodide and subjected to fluorescent activated cell sorting to determine 1185 
the proportion of cells in various phases of the cell cycle. In an asynchronously cycling cell 1186 
population there was no significant difference (two sided t-test) between the proportion of cells in 1187 
G0/G1, S and G2/M phases between control cells expressing the pCAG control construct and those 1188 
overexpressing Cerox1. P > 0.05, n = 4 biological replicates. 1189 
 1190 
 1191 
 1192 
Figure 3 – figure supplement 3 1193 
Increases in mitochondrial complex I and complex IV activities are not due to an increase in 1194 
mitochondrial copy number. (A) The mitochondrial-to-nuclear genome ratio was calculated by 1195 
amplifying the nuclear genes -actin and beclin-1 and the mitochondrial genes Nd1 and Nd2 and 1196 
calculating the ratio. Primers were designed to regions in ND1 and ND2 that would not amplify any 1197 
nuclear pseudogenes. No significant difference in mitochondrial genome number was found 1198 
between control and Cerox1 overexpression N2A cells (P = 0.99, two-tailed Student’s t-test, errors 1199 
s.d, n = 12). (B) Western blots were performed using an OXPHOS antibody cocktail on protein 1200 
extracted from control and overexpression N2A cells. Densitometry analysis indicated no significant 1201 
difference in the amount of OXPHOS complexes between control and experimental cell lines. CI, 1202 
complex I; CII, complex II; CIII, complex III; CIV, complex IV; CV, complex V; NDUFB8, NADH 1203 
dehydrogenase (ubiquinone) 1 beta subcomplex, 8;  SDHB, succinate dehydrogenase complex, 1204 
subunit B; UQCRC2, ubiquinol cytochrome c reductase core protein 2; MTCO1, mitochondrial 1205 
cytochrome oxidase 1; ATP5A, ATP synthase alpha subunit. 1206 
 1207 
 1208 
 1209 
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Figure 5 – figure supplement 5 1210 
(A) Expression profile of mouse miR-28-5p, miR-138-5p, miR-370-3p, miR-488-3p and miR-708-5p in 1211 
N2A cells as measured by quantitative PCR and nanostring.  Both techniques reveal the same trend 1212 
in expression in N2A cells.  Highest to lowest expression is as follows:  miR-138-5p>miR-28-1213 
5p>miR488-3p/miR-708-5p>miR-370-3p.  (B) Tissue profiling miRNA expression data from Landgraf 1214 
et al., (2007) indicates the restricted expression of mmu-miR-488-3p to the central nervous system, 1215 
N2A cells and embryonic development.  Expression of mmu-miR-488-3p was not detected in any 1216 
other tissue surveyed (data not shown). (C)  Mouse tissue short RNA sequencing (106) illustrates the 1217 
high expression of miR-488-3p in the mouse brain, where it is ranked 42nd of 901 small RNAs 1218 
detected in the brain.  (D) Fluorescent in situ hybridization no probe control.  Some back ground 1219 
nuclear signal can be detected in the Fast Red channel (used to image the miRNA probe), but there 1220 
was no detectable background for Alexa Fluor-488 (lncRNA detection).  Scale bar = 5 m. 1221 
 1222 
 1223 
Supplementary file 1 1224 
Association of CEROX1 single nucleotide polymorphism on anthropomorphic traits.  Data was 1225 
accessed through http://geneatlas.roslin.ed.ac.uk/ 1226 
 1227 
Supplementary file 2 1228 
Differentially expressed genes after overexpression of mouse Cerox1 1229 
 1230 
Supplementary file 3 1231 
MRE predictions for Nduf subunit transcripts 1232 
Supplementary file 4 1233 
shRNA oligos and PCR primers 1234 
1235 
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